German diagnostics firm garners €22M

Germany's MTM Laboratories has raised €22 million in its third round of venture funding. The developer says that much of that money will go to the development and commercialization of its diagnostic and screening devices for cervical cancer. HBM BioVentures and HBM BioCapital led the round.

"MTM Laboratories is taking a unique marker approach to the screening and diagnosis of cervical cancer, the largest existing screening market in oncology," said Dr. Erich Platzer, founding partner and investment advisor of HBM Partners. "We feel that the strength of the science combined with the development and commercialization experience of the team makes MTM a very attractive investment."

- see the release for more information

PLUS: France's Faust Pharmaceuticals has raised 8.2 million euros in bridge financing. Faust says the money is the first tranche in a €25 to €35 million financing round. Release

Suggested Articles

Bristol Myers Squibb may have bounced Jounce from its roster of inherited partners, but it’s hanging onto Anokion, a Swiss autoimmune-focused biotech.

The priority review action date sets Bristol Myers up to win approval for the bluebird-partnered anti-BCMA CAR-T therapy in late March.

The unidentified biotechs are drawn from the portfolio of a €150 million life science-focused fund that Index Ventures set up.